The 100% figure refers to specified experimental groups, not to every animal across all protocols. Interpretation depends on the tested material, control group, intervention timing and endpoint.
01
Cell studies — In Vitro
The 2006 document describes cinnamon-extract and extract-fraction assays, including protection of Vero cells against HSV-1 cytopathic effects and hemolysis-related assays for influenza viruses. These endpoints are not necessarily equivalent to direct PFU/ml counts.
02
Mouse studies — In Vivo
Figures 9–11 report body-weight changes, mortality and survival in mouse groups. Example 9 describes zero deaths among 10 mice given virus pre-exposed to extract.
03
Post-exposure experiments
Example 11 investigates cinnamon-extract fraction administered after Sendai virus exposure. The main reported endpoint is change in body weight over follow-up, not one universal survival percentage.
04
Oral versus subcutaneous routes
Example 12 evaluates a subsequent viral challenge following prior administration of a virus–extract mixture. Its route comparison is not a human clinical trial of an oral product.
05
Bio-emulsion matrix development
Galoz Kaneti’s 2020 APA-013 disclosure describes Ceylon cinnamon oil-and-water formulations, surfactants, preparation approaches and emulsion observations. Results from the 2006 extract cannot automatically be attributed to every later CVT formulation.
BIOEMULSION LAB / SCIENTIFIC VISUALIZATION
Source map: cinnamon extracts versus the bio-emulsion matrix
The two patent documents cover different research stages. Select a document to see its actual scope without transferring results between formulations.
The 2006 patent application reports assays using cinnamon extracts/fractions, including cellular studies and animal models.
Original schematic • not raw experimental data or a microscope image
DOCUMENT PROVENANCE
Identified source documents
The 2006 patent document names Michael Ovadia as inventor, while the 2020 APA-013 document names Galoz Kaneti. Named inventorship does not establish who physically performed every experiment.
2006 · CINNAMON EXTRACT
US20060275515A1 (2006): Antiviral Preparations Obtained from a Natural Cinnamon Extract — Examples 7–12, Figures 9–14.
2020 · BIO-EMULSION FORMULATION
APA-013 (2020): Cinnamon Cortex Powder-Based Emulsion and Uses Thereof — formulation examples and composition disclosures.
RESEARCH NOTES / DEEP DIVE
A practical guide to reading the protocols
A scientifically useful result begins with a clear description of what was tested, how it was compared and which outcome was measured.
Key points for critical reading
01
1 · Test material and control
Was the sample a cinnamon extract, an isolated fraction or an emulsion? What did the comparison group receive? The precise material is part of the study design, not a minor detail.
02
2 · Exposure order and outcome
Was the virus mixed with material before inoculation, or was material administered after exposure? Was the endpoint CPE, hemolysis, survival, body weight or emulsion size? Each answers a different question.
03
3 · Sample size and inference
Group size, number of replicates, follow-up period and statistical analysis affect how the findings may be interpreted. A statistically significant comparison does not establish equivalence between treatments.
Frequently asked questions
Why separate the 2006 and 2020 documents?
An outcome measured for one material and protocol cannot automatically be transferred to a later formulation.
What is DLS?
Dynamic light scattering characterizes particle-size distributions. It does not directly measure antiviral efficacy.